← Shandong Buchang Pharmaceuticals overview

Shandong Buchang Pharmaceuticals vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shandong Buchang Pharmaceuticals Co Ltd (603858.CG)

Q3 2026
▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

  • Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.

    This is the single biggest force pushing the stock down this period.

  • New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.

    Shows the pipeline progress that partly offsets the weak earnings.

  • Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.

    These are the period's other concrete actions affecting the company's growth outlook.

  • Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.

    It is a new strategic move that could support longer-term growth.

August 2026
▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

  • Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.

    This is the single biggest force pushing the stock down this period.

  • New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.

    Shows the pipeline progress that partly offsets the weak earnings.

  • Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.

    These are the period's other concrete actions affecting the company's growth outlook.

  • Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.

    It is a new strategic move that could support longer-term growth.

Latest
▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

  • Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.

    This is the single biggest force pushing the stock down this period.

  • New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.

    Shows the pipeline progress that partly offsets the weak earnings.

  • Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.

    These are the period's other concrete actions affecting the company's growth outlook.

  • Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.

    It is a new strategic move that could support longer-term growth.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.